Medium materiality4/10
UBS raises Biogen price target to $300 from $270
Why it may matterVerify against the original reporting
Bullish analyst revision, with the usual uncertainty of a price-target update.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
UBS raised its BIIB price target by about 11% to $300, versus a posted price of $252.31. This is a positive analyst revision, though a target remains an opinion rather than a forecast guarantee.
- UBS raised its BIIB price target to $300 from $270.
- The posted price was $252.31.
Key facts
- 01
Target: $300
- 02
Posted price: $252.31
- 03
Analyst firm: UBS
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.